Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability.

Updates on zanubrutinib monotherapy in high-risk, treatment-naïve (TN) CLL from the SEQUOIA study.1 These long-term results continue to support zanubrutinib as an effective, tolerable frontline option for CLL, including in those with high-risk features.1 Zanubrutinib in R/R CLL Long-term extension from the Phase 3 ALPINE study continues to demonstrate sustained PFS benefit and response rates regardless of del(17p) status.2 With up to 6 years of follow-up, patients with del(17p) treated with zanubrutinib demonstrated sustained efficacy comparable with the overall population, along with a similar safety profile.2 This communication may include descriptions of products or uses that are not approved by the local Authorities.

In this short overview, hematologist Alessandra Tedeschi and pharmacologist Federico Pea outline the key pharmacotherapy considerations in the use of the BTK inhibitors ibrutinib, zanubrutinib, and acalabrutinib.